Scientists find rare double-star system where one star orbited inside the other
When you buy through links on our articles, Future and its syndication partners may earn a commission.
Astronomers may have discovered a rare type of binary star system, where one star used to orbit inside its partner.
In the new study, astronomers investigated a pulsar known as PSR J1928+1815 located about 455 light-years from Earth. A pulsar is a kind of neutron star, a corpse of a large star that perished in a catastrophic explosion known as a supernova. The gravitational pull of the star's remains would have been strong enough to crush together protons and electrons to form neutrons, meaning a neutron star is mostly made of neutrons. That makes it very (very) dense.
Pulsars are spinning neutron stars that emit twin beams of radio waves from their magnetic poles. These beams appear to pulse because astronomers see them only when a pulsar pole is pointed at Earth. The researchers estimate this particular pulsar was born from a hot blue star more than eight times the sun's mass.
Using the Five-hundred-meter Aperture Spherical radio Telescope (FAST) in China, the world's largest single-dish telescope, the astronomers discovered PSR J1928+1815 had a companion, a helium star with about 1 to 1.6 times the sun's mass. This star has lost most — or all — of its outer layers of hydrogen, leaving behind a core made up mostly of helium.
These stars in this pair are currently only about 700,000 miles (1.12 million kilometers) apart, or about 50 times closer than Mercury is to the sun, study co-author Jin-Lan Han, chair of the radio astronomy division of the National Astronomical Observatories of the Chinese Academy of Sciences in Beijing, told Space.com. They complete an orbit around each other in just 3.6 hours.
PSR J1928+1815 is a millisecond pulsar, which means it whirls extraordinarily rapidly, spinning nearly 100 times a second. Millisecond pulsars typically reach these dizzying speeds as they cannibalize nearby companions — the inrushing material makes them gyrate faster and faster.
Previous research suggested that, as millisecond pulsars feed on their partners, these binary systems may experience a "common envelope" phase, in which the pulsar orbits within the outer layers of its companion. However, scientists have never detected such exotic binaries — perhaps until now.
Related Stories:
— This astronomer found a sneaky extra star in James Webb Space Telescope data
— Hubble Telescope sees wandering black hole slurping up stellar spaghetti
— Giant young star is growing by 2 Jupiter masses every year, new study shows
Using computer models, the researchers suggest the members of this newfound binary started at a distance from each other about twice that between Earth and the sun (185 million miles, or 299 million km), Han said. The pulsar would have then started siphoning off its companion's outer layers, forming a common envelope around them both. After roughly 1,000 years, the pulsar would have spiraled close to its partner's core, which likely flung away the last of this envelope, leaving behind a tightly bound binary system.
Based on the estimated number of binary stars in the Milky Way that roughly match this newfound system, the researchers suggest only 16 to 84 counterparts of PSR J1928+1815 and its companion may exist in our galaxy. (For context, the Milky Way hosts about 100 billion to 400 billion stars.)
The scientists detailed their findings online May 22 in the journal Science.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
12 hours ago
- Yahoo
Scientists edge closer to unleashing virtually unlimited power source — here's when it could finally go live
China's Burning Plasma Experimental Superconducting Tokamak fusion reactor aims to create five times the energy output to revolutionize global energy production. Located in Hefei, China, the "BEST" reactor uses a complex tokamak design. According to Sustainability Times' reporting on May 8, it utilizes a doughnut-shaped vessel that heats plasma to temperatures hotter than on the surface of the sun. It causes hydrogen isotopes to fuse and form helium, which releases massive amounts of energy. Nuclear fusion is preferable to nuclear fission because it creates less radioactive waste. Radioactive waste must be carefully managed and often requires ample storage space. Eliminating the need for waste management streamlines energy production. The process also releases minimal harmful gases into the atmosphere. Burning coal, natural gas, and oil creates dangerous carbon pollution. These heat the planet, destabilizing the climate, upsetting ecosystems, and furthering the spread of diseases. While other fusion projects, such as China's Experimental Advanced Superconducting Tokamak and the United States' Smallest Possible ARC prototype fusion machine, have made strides, the BEST reactor is a major breakthrough. The United States' SPARC reactor only promises to double its energy output; BEST aims to quintuple its output. This high energy output could vastly improve the world's sustainability. With fusion, energy would be near-limitless and thus easily accessible and substantially more affordable. People could enjoy lower utility bills and consistent, reliable energy. The innovative reactor would help slow down climate change and lead to a cleaner, cooler future, while helping people save money and access clean energy. Reducing energy pollution will benefit every human, reducing the health hazards of breathing polluted air or drinking contaminated water. The BEST reactor is slated for delivery by November 2027, and it could be the beginning of an energy revolution. However, there are ways to embrace innovative clean energy solutions now. If you want to lower your utility bills and reduce your home's pollution, you can install solar panels. They could bring the cost of home energy down to or near $0. To get started, use EnergySage's free service that makes it easy to compare quotes from vetted local installers and save up to $10,000 on solar installations. The environmental benefits of fusion combined with the financial savings and high energy output mean China's BEST reactor could change how we think about and use energy. It's an important leap forward in nuclear fusion technology and a step toward a healthier Earth. Should we be harnessing the ocean to power our homes? Absolutely Leave it be It depends I'm not sure Click your choice to see results and speak your mind. Join our free newsletter for weekly updates on the latest innovations improving our lives and shaping our future, and don't miss this cool list of easy ways to help yourself while helping the planet.
Yahoo
18 hours ago
- Yahoo
The British Medical Journal Publishes Study Results on Sacituzumab Tirumotecan for Previously Treated EGFR-Mutant Advanced NSCLC
CHENGDU, China, June 6, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech", today announced that results from its registrational study (OptiTROP-Lung03) evaluating sacituzumab tirumotecan (sac-TMT) versus docetaxel in patients with previously treated advanced EGFR-mutant non-small cell lung cancer (NSCLC) have been published in The British Medical Journal (impact factor: 93.6). These data were also presented as an oral presentation in the Lung Cancer—Non–Small Cell Metastatic session (Abstract #8507) at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. Based on the encouraging data from this study, sac-TMT was approved for marketing by the National Medical Products Administration (NMPA) for the treatment of adult patients with epidermal growth factor receptor (EGFR) mutant-positive locally advanced or metastatic non-squamous NSCLC following progression on EGFR-tyrosine kinase inhibitor (TKI) therapy and platinum-based chemotherapy in March 2025. This marks the first global approval of a TROP2 ADC for a lung cancer indication. The published results are based on OptiTROP-Lung03, an open-label, randomized, multicenter registrational study evaluating the efficacy and safety profile of sac-TMT monotherapy versus docetaxel for the treatment of patients with locally advanced or metastatic EGFR-mutant NSCLC who have failed after treatment with an EGFR-TKI and platinum-based chemotherapy. A total of 137 patients with advanced EGFR-mutant NSCLC who had progressed after EGFR-TKI and platinum-based chemotherapy were randomized (2:1) to receive sac-TMT (5 mg/kg once every 2 weeks) or docetaxel (75 mg/m2 once every 3 weeks) until disease progression, intolerable toxicity or other reason for discontinuation, with a median follow-up time of 12.2 months (Data cutoff date: December 31, 2024). Sac-TMT achieved statistically significant and clinically meaningful outcomes compared to docetaxel: Confirmed objective response rate (ORR) (As assessed by blinded independent review committee (BIRC): 45% (95% CI, 35-56) vs 16% (95% CI, 7-30). Median progression-free survival (PFS) (As assessed by BIRC: 6.9 months [sac-TMT; 95% CI, 5.4-8.2] vs 2.8 months [docetaxel; 95% CI, 1.6-4.1], hazard ratio (HR)= 0.30 [range, 0.20 -0.46], one-sided p<0.0001; as assessed by investigator (INV): 7.9 months [sac-TMT; 95% CI, 6.2-9.5] vs 2.8 months [docetaxel; 95% CI, 1.5-3.8], HR=0.23 [95% CI, 0.15-0.36], one-sided p<0.0001). With 36.4% of patients in docetaxel group crossing over to receive sac-TMT, median overall survival (OS) was not reached (NR) for both groups (HR=0.49; 95% CI, 0.27-0.88; one-sided p=0.007). The median OS analysed by pre-specified rank-preserving structural failure time (RPSFT) model adjusted for crossover was 9.3 months for docetaxel and NR for sac-TMT (HR=0.36; 95% CI, 0.20-0.66). Efficacy benefit favored patients with sac-TMT over docetaxel across all pre-specified subgroups, including prior EGFR-TKI therapy, brain metastases, EGFR mutation type, etc. Grade ≥ 3 treatment-related adverse events (TRAEs) occurred in 56.0% of patients in sac-TMT group vs 71.7% in docetaxel group. The results demonstrated that sac-TMT monotherapy achieved statistically significant and clinically meaningful improvements in objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) compared to docetaxel, with a manageable safety profile. Sac-TMT is being extensively studied in the NSCLC field. Covering treatment settings from later-line therapy to early-stage postoperative adjuvant therapy, including both monotherapy and combination regimens. Currently, five company-led registrational clinical studies for sac-TMT in NSCLC are underway in China. Meanwhile, Merck Sharp & Dohme(the tradename of Merck & Co., Inc., Rahway, NJ, USA)is also conducting five global Phase III clinical trials of sac-TMT for NSCLC in regions where it has exclusive rights. Professor Li Zhang, National Lead Principal Investigator, Medical Oncologist and Deputy Director of the Lung Cancer Research Centre at Sun Yat-Sen University, stated: "EGFR mutation is the most common driver alteration in NSCLC. The prevalence of EGFR mutations reaches 28.2% among NSCLC patients in China. Although third-generation EGFR-TKIs have become the standard of care for advanced EGFR-mutant NSCLC and may significantly improve PFS, acquired resistance remains inevitable. Combining EGFR-TKIs with chemotherapy can offer additional survival benefits to some patients, but this approach is limited by safety concerns and may compromise future treatment options, posing significant clinical challenges. The publication of the OptiTROP-Lung03 study in the British Medical Journal marks a major milestone—not only highlighting international recognition of this study outcomes in lung cancer, but also demonstrating the global competitiveness of sac-TMT as a novel TROP2 ADC." Dr. Michael Ge, CEO of Kelun-Biotech, commented: "We are thrilled to see the OptiTROP-Lung03 study published in a top-tier journal. Currently, EGFR-TKIs and chemotherapy remain the standard of care for patients with EGFR-mutant advanced NSCLC, but the challenge of increasing efficacy with manageable tolerability. The results from OptiTROP-Lung03 highlight significant survival benefits with manageable safety profile and suggest that sac-TMT could emerge as a new standard of care for this population. We remain committed to working with our partners to establish sac-TMT as a new standard of care for this patient population and improve outcomes for lung cancer patients worldwide." Registrational Study Led by Kelun-Biotech OptiTROP-Lung03: Sac-TMT monotherapy versus docetaxel for locally advanced or metastatic EGFR-mutant NSCLC after treatment failure with EGFR-TKI and platinum-containing chemotherapy; OptiTROP-Lung04: Sac-TMT monotherapy versus pemetrexed in combination with platinum for locally advanced or metastatic non-squamous NSCLC with EGFR mutations that have failed EGFR-TKI therapy; OptiTROP-Lung05: Sac-TMT combined with pembrolizumab versus chemotherapy combined with pembrolizumab for first-line treatment of PD-L1-positive locally advanced or metastatic NSCLC; OptiTROP-Lung06: Sac-TMT combined with pembrolizumab versus chemotherapy combined with pembrolizumab for the first-line treatment of PD-L1-negative locally advanced or metastatic non-squamous NSCLC; OptiTROP-Lung07: First-line treatment of locally advanced or metastatic NSCLC with EGFR mutations by sac-TMT in combination with ositinib. Registrational Study Led by MSD NSCLC not achieving a pCR after neoadjuvant therapy followed by surgery. NSCLC expressing PD-L1 >50% pre-treated NSCLC with EGFR mutations or other genomic alterations EGFR-mutated, advanced non-squ NSCLC progressed on prior EGFR-TK metastatic sg NSCLC About sac-TMT Sac-TMT, a core product of the Company, is a novel human TROP2 ADC in which the Company has proprietary intellectual property rights, targeting advanced solid tumors such as NSCLC, BC, gastric cancer (GC), gynecological tumors, among others. Sac-TMT is developed with a novel linker to conjugate the payload, a belotecan-derivative topoisomerase I inhibitor with a drug-to-antibody-ratio (DAR) of 7.4. Sac-TMT specifically recognizes TROP2 on the surface of tumor cells by recombinant anti-TROP2 humanized monoclonal antibodies, which is then endocytosed by tumor cells and releases KL610023 intracellularly. KL610023, as a topoisomerase I inhibitor, induces DNA damage to tumor cells, which in turn leads to cell-cycle arrest and apoptosis. In addition, it also releases KL610023 in the tumor microenvironment. Given that KL610023 is membrane permeable, it can enable a bystander effect, or in other words kill adjacent tumor cells. In May 2022, the Company licensed the exclusive rights to MSD (the tradename of Merck & Co., Inc., Rahway, NJ, USA) to develop, use, manufacture and commercialize sac-TMT in all territories outside of Greater China (includes Mainland China, Hong Kong, Macao, and Taiwan). To date, two indications for sac-TMT have been approved and marketed in China for the treatment of adult patients with unresectable locally advanced or metastatic TNBC who have received at least two prior systemic therapies (at least one of them for advanced or metastatic setting) based on the OptiTROP-Breast01 study and EGFR mutation-positive locally advanced or metastatic non-squamous NSCLC following progression on EGFR-TKI therapy and platinum-based chemotherapy based on the OptiTROP-Lung03 study. Sac-TMT became the first domestic ADC with global intellectual property rights to be fully approved for marketing. It is also the world's first TROP2 ADC to be approved for marketing in a lung cancer indication. In addition, two new indication applications for sac-TMT for the treatment of adult patients with EGFR-mutant locally advanced or metastatic NSCLC who progressed after treatment with EGFR-TKI therapy and with unresectable locally advanced, metastatic hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) BC who have received prior endocrine therapy and other systemic treatments in the advanced or metastatic setting were accepted by the National Medical Products Administration (NMPA), and were reviewed via the priority review and approval process. As of today, the Company has initiated 8 registrational clinical studies in China. MSD has initiated 14 ongoing Phase 3 global clinical studies of sac-TMT as a monotherapy or with pembrolizumab or other agents for several types of cancer. These studies are sponsored and led by MSD. About Kelun-Biotech Kelun-Biotech( a holding subsidiary of Kelun Pharmaceutical ( which focuses on the R&D, manufacturing, commercialization and global collaboration of innovative biological drugs and small molecule drugs. The company focuses on major disease areas such as solid tumors, autoimmune, inflammatory, and metabolic diseases, and in establishing a globalized drug development and industrialization platform to address the unmet medical needs in China and the rest of world. The Company is committed to becoming a leading global enterprise in the field of innovative drugs. At present, the Company has more than 30 ongoing key innovative drug projects, of which 3 projects have been approved for marketing, 1 project is in the NDA stage, and more than 10 projects are in the clinical stage. The company has established one of the world's leading proprietary ADC platforms, OptiDC™, and has 1 ADC project approved for marketing, 1 ADC project in NDA stage, and multiple ADC and novel coupled drug products in clinical or preclinical research stage. For more information, please visit Media: klbio_pr@ View original content to download multimedia: SOURCE Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
20 hours ago
- Yahoo
Gene-hacked microbe pulls rare earths and traps carbon 58x faster than nature
In the war for clean energy and climate survival, scientists have found an unlikely ally: a metal-eating microbe. Tiny but tenacious, Gluconobacter oxydans is being reprogrammed to replace heavy machinery and toxic chemicals in the extraction of rare earth elements. But this microbe isn't just pulling metals from stone. It's also accelerating the Earth's natural ability to trap carbon dioxide, offering a two-for-one deal in the fight against climate change. Armed with genetic tweaks that turbocharge its acid production and unlock hidden biochemical abilities, G. oxydans is proving to be more efficient than new research, scientists at Cornell University boosted its rare earth extraction power by up to 73 percent—without the environmental damage of traditional mining. The same microbe can also accelerate natural carbon capture by 58 times, transforming ordinary rocks into long-term CO₂ storage systems. 'More metals will have to be mined in this century than in all of human history, but traditional mining technologies are enormously environmentally damaging,' said Buz Barstow, associate professor of biological and environmental engineering in the College of Agriculture and Life Sciences, in a release.'Currently, the U.S. has to obtain almost all of these elements from foreign sources, including China, creating a risk of supply-chain disruption.' Metals like magnesium, iron, and calcium naturally react with carbon dioxide to form minerals that lock the gas away for good. Cornell's engineered microbes supercharge this process by breaking down rock faster, exposing more metal to CO₂, and turning the Earth itself into a carbon trap. 'What we're trying to do is take advantage of processes that already exist in nature but turbocharge their efficiency and improve sustainability,' said Esteban Gazel, the Charles N. Mellowes Professor in Cornell Engineering. To push the microbes' potential further, Cornell scientists dug into its genetic blueprint. In one study, they discovered that with just two genome edits, G. oxydans could become far more effective at dissolving rock—one tweak increased acid production, while the other removed internal limits, dramatic increasing rare earth recovery. But acid wasn't its only tool. A second study revealed that the microbe uses other, previously unknown pathways to extract metals. By knocking out genes one by one in a high-performing strain, researchers identified 89 genes tied to bioleaching—68 of which had never before been linked to the process. That breakthrough helped boost extraction efficiency by more than 100 percent. In parallel, a third paper showed that G. oxydans can speed up natural carbon capture without relying on high temperatures, pressure, or harsh chemicals. As it breaks down magnesium- and iron-rich rocks, those elements bind with carbon dioxide to form solid minerals like limestone, permanently locking the carbon away.'This process can occur in ambient conditions, at low temperature, and it doesn't involve the use of harsh chemicals,' said Joseph Lee, a Ph.D. student and lead author. 'It naturally draws down CO2 and stores it permanently as minerals. We're also recovering other energy-critical metals like nickel as byproducts. It's a two-fold solution.' With funding from the National Science Foundation, the Department of Energy, Cornell Atkinson, and alumni donors, the work is now moving from the lab to the real world. The research, published in Communications Biology and Scientific Reports, was led by Alexa Schmitz, now CEO of REEgen, an Ithaca-based startup working to commercialize the technology.